Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)

Market Cap	69.43B +8.5%
Revenue (ttm)	5.48B +35.9%
Net Income	949.28M +142.0%
EPS	0.84 +144.7%
Shares Out	1.11B
PE Ratio	74.40
Forward PE	68.28
Dividend	0.53 (0.79%)
Ex-Dividend Date	Sep 4, 2026

Volume	3,495,193
Open	67.96
Previous Close	62.60
Day's Range	61.42 - 67.96
52-Week Range	42.38 - 80.83
Beta	-0.21
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About SHE:002653

Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. Haisco Pharmaceutical Group Co., Ltd. has licensing and research collaboration with Eli Lilly and Company to develop medicines across multiple therapeutic areas. The company was formerly known as Xizang Haisco Pharmac...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 5,597
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002653

Financial Performance

In 2025, SHE:002653's revenue was 4.39 billion, an increase of 17.91% compared to the previous year's 3.72 billion. Earnings were 259.58 million, a decrease of -34.36%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error